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A novel ABCD1 gene mutation in a  patient with X-linked 
adrenoleukodystrophy with atypically normal plasma levels of very 
long chain fatty acids
Plazmada çok uzun zincirli yağ asidi düzeyleri normal olan bir X’e bağlı adrenolökodistrofi 
hastasında daha önce tanımlanmamış bir ABCD1 gen mutasyonu
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ABSTRACT
X-linked adrenoleukodystrophy (X-ALD) is a rapidly progressive 
neurodegenerative disorder characterized by progressive 
demyelination of central nervous system, adrenocortical 
insufficiency and elevated levels of very long chain fatty acids 
(VLCFAs) in plasma and tissues. Here, a seven-year-old patient 
who had atypically normal plasma levels of VLCFAs and whose 
diagnosis of X-ALD is confirmed by a novel mutation of ABCD1 
gene is described. 
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ÖZ
X’e bağlı adrenolökodistrofi (X-ALD) hızlı ilerleyici 
nörodejeneratif bir hastalık olup,  santral sinir sisteminin ilerleyici 
demiyelinizasyonu, adrenokortikal yetersizlik ve plazma çok 
uzun zincirli yağ asidi (VLCFAs) düzeylerinin yükselmesiyle 
karakterizedir. Bu yazıda, plazma VLCFA düzeyleri beklenenin 
aksine normal sınırlarda olan ve X-ALD tanısı ABCD1 geninin 
daha önce tanımlanmamış bir mutasyonunun gösterilmesiyle 
konulan 7 yaşındaki erkek hasta sunulmuştur.
Anahtar kelimeler: X-ALD, ABCD1 geni, VLCFA
Introduction
X-linked adrenoleukodystrophy (X-ALD) is a rapidly 
progressive neurodegenerative disorder resulting from 
dysfunction of a peroxisomal adenosine triphosphate 
(ATP)-binding fatty-acid transporter due to mutations 
in the ABCD1 gene (NM_000033.3) localized to Xq28 
[1]. It is characterized by progressive demyelination of 
central nervous system, adrenocortical insufficiency and 
elevated levels of very long chain fatty acids (VLCFAs) in 
plasma and tissues. Diagnosis is usually based on clinical, 
radiological and serological examinations and it should be 
confirmed with molecular analysis of ABCD1 gene [2, 3]. 
To date, more than 1300 mutations have been reported and 
listed in X-ALD database [4]. In this report, a seven-year-
old Turkish patient who had atypically normal plasma levels 
of  VLCFAs and whose diagnosis of X-ALD is confirmed 
by a novel mutation of ABCD1 gene is described. 
Case Report
A seven-year-old male patient was admitted to our outpatient 
clinic with complaints of weakness of lower extremities, 
difficulty in spatial orientation, aggressive behavior and 
inarticulate speech. He appeared to be healthy in his first six 
years and he achieved developmental milestones appropriate 
with his age. During the last year before his admission to our 
department, diminished school performance and inattention 
were noted by his teachers. 
His physical examination revealed reduced muscle 
strength as 3/5 in lower extremities, hyperreflexia of both 
superior and inferior extremities, pathological Babinski sign 
and inarticulate speech. Results of extensive examinations 
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including hematological and biochemical investigations, 
quantitative amino acid analysis, acylcarnitine analysis 
performed by tandem mass spectrometry (MS), urinary 
organic acids, plasma lactate and ammonia levels were 
found normal.
His  brain T2 weighted  magnetic resonance  imaging 
(MRI) findings   showed high signal intensity lesions in 
the parieto-occipito-fronto-temporal periventricular white 
matter, especially around the atrium of the lateral ventricle, 
the posterior half of the corpus callosum, posterior limb 
of the internal capsule and along the pyramidal tract of 
the brainstem. As the radiological findings were highly 
predictive of X-ALD, fasting plasma levels of VLCFAs 
were measured. Plasma VLCFAs levels were normal as 
C22:0=42 µmol/L (normal: 0-105µmol/L), C24:0=50,2 
µmol/L (normal:0-80 µmol/L) and C26:0=0,89µmol/
L(normal:0-0,92 µmol/L). His C24:0/C22:0 and C26:0/
C22:0 ratios were slightly elevated at 1,2 (normal:0,51-1,19) 
and 0,02 (normal:0,006-0,014) respectively. 
Atypical pattern of normal plasma levels of VLCFAs 
despite the existence of neurological and  clinical 
manifestations and MRI findings compatible with X-ALD 
led the necessity of molecular analysis of ABCD1 gene. 
Genomic DNA was extracted from peripheral blood 
obtained from the patient after taking the inform consent 
of the parents. The coding region of  ABCD1 including the 
intron-exon boundaries of all exon 1-10 were amplified 
using the polymerase chain reaction (PCR). Molecular 
analysis of ABCD1 gene which was applied by next-
generation sequencing (NGS) showed the c.713_730del18 
mutation in homozygous state. As this mutation of the 
ABCD1 gene has not been reported before, molecular 
analysis of ABCD1   gene of the mother was also performed. 
The analysis result of the mother showed c.713_730del18 
mutation in heterozygote state. Both of the mutations were 
confirmed by Sanger sequencing. Two single-nucleotide 
polymorphisms were detected (c.2019C>T (p.F673=); 
c.2190G>A (p.P730=) ) that were previously reported in 
X-ALD database [4]. His  initial diagnosis was based on 
neurological and clinical manifestations and MRI findings. 
His diagnosis was confirmed by genetic evidence of an 
ABCD1  mutation.
Discussion
Adrenoleukodytsrophy (ALD) is mainly classified 
as cerebral ALD (childhood, adolescent and adult 
forms), adrenomyeloneuropathy, Addison-only, 
olivopontocerebellar ALD and asymptomatic ALD [3]. 
Clinical manifestations depend on demyelination of central 
nervous system and adrenocortical insufficiency. The 
childhood cerebral ALD form is the most severe phenotype 
of the disease with onset of neurological symptoms between 
5 and 12 years of age. Initial symptoms may be subtle and 
nonspecific as diminished school performance, attention 
deficit and behavioral changes. Our patient was seven 
years old when he was admitted to our department but his 
initial symptoms,  like   diminished school performance and 
inattention started a year ago.  Devastating neurological 
symptoms such as severe visual and hearing impairment, 
quadriplegia and cerebellar ataxia and seizures can develop 
following the initial symptoms as the disease progresses. 
Brain MRI reveals characteristically symmetrical cerebral 
lesions involving the white matter in the parietal and 
occipital lobes [5]. Brain MRI findings of our patient 
showed high signal intensity lesions in the parieto-occipito-
fronto-temporal periventricular white matter.
In the  X-ALD database, more than 1,300 mutations 
have been reported to date in ABCD1 gene. These mutations 
were described as 51% missense mutations, 11% nonsense 
mutations, 28% frameshift mutations, 6% amino acid 
insertions/deletions, and 3% deletion of one or more exons. 
There is no clear correlation between the phenotype and 
genotype of ALD patients [6].
Elevated levels of VLCFAs represent the standard 
biomarker for diagnosis of X-ALD. Elevation of VLCFAs 
due to accumulation is observed in most of  male X-ALD 
patients regardless of age, metabolic status, or clinical 
symptoms. The most frequently used diagnostic parameter 
is the concentration of total C26:0. In addition, ratio of 
C26:0/C22:0 or C24:0/C22:0 can be used, because C22:0 
remains unchanged or is even slightly reduced in plasma 
samples of X-ALD patients. As the increased  measurement 
of VLCFAs can only be detected in  85% of  female carriers, 
additional mutation analysis of the ABCD1 gene is necessary 
for definite diagnosis of heterozygous X-ALD females [7].
In our patient, although the imaging findings and 
neurological symptoms were compatible with X-ALD, 
levels of plasma VLCFAs were in normal ranges. His 
diagnosis was confirmed by genetic evidence of an ABCD1 
mutation. c.713_730del18 mutation in homozygous state in 
the ABCD1 gene has not been reported before. 
In conclusion, normal plasma levels of VLCFAs do not 
exclude the diagnosis of X-ALD in the existence of clinical 
and radiological suspicion. Mutational analysis of the 
ABCD1 gene can lead to  proper diagnosis. 
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